TerrAscend (TSNDF) Non-Current Deferred Tax Liability (2021 - 2026)
TerrAscend's (TSNDF) quarterly Non-Current Deferred Tax Liability came in at $8.3 million in Q1 2026, down 6.3% year-on-year from $8.9 million in Q1 2025, and up 3.74% on a QoQ basis from $8.0 million in Q4 2025.
TerrAscend (TSNDF) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $8.3 million in Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 6.3% year-over-year to $8.3 million in Q1 2026; TTM through Mar 2026 was $8.3 million, a 6.3% decrease from a year earlier, with the FY2025 full-year figure at $8.0 million, down 4.78% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $8.3 million, up from $8.0 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for TSNDF reached as high as $73.1 million in Q2 2022 and fell as low as $8.0 million in Q4 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $26.1 million across 5 years, with a median of $16.9 million in 2024.
- Across the five-year window, Non-Current Deferred Tax Liability surged 115.15% in 2022 and plunged 57.68% in 2024, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $30.7 million in 2022, then tumbled by 44.06% to $17.2 million in 2023, then plunged by 50.93% to $8.4 million in 2024, then slipped by 4.78% to $8.0 million in 2025, then rose by 3.74% to $8.3 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $8.3 million in Q1 2026, $8.0 million in Q4 2025, and $8.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.33 Mn |
| Mar 31, 2026 | 8.33 Mn |
| Dec 31, 2025 | 8.03 Mn |
| Dec 31, 2025 | 8.03 Mn |
| Sep 30, 2025 | 8.72 Mn |
| Sep 30, 2025 | 8.72 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Jun 30, 2025 | 9.03 Mn |
| Mar 31, 2025 | 8.89 Mn |
| Mar 31, 2025 | 8.89 Mn |
| Dec 31, 2024 | 8.43 Mn |
| Dec 31, 2024 | 8.43 Mn |
| Sep 30, 2024 | 16.19 Mn |
| Sep 30, 2024 | 16.19 Mn |
| Jun 30, 2024 | 16.76 Mn |
| Jun 30, 2024 | 16.76 Mn |
| Mar 31, 2024 | 16.92 Mn |
| Mar 31, 2024 | 16.92 Mn |
| Dec 31, 2023 | 17.18 Mn |
| Dec 31, 2023 | 17.18 Mn |